Quantumzyme Corp. (QTZM)
Oxford Ledge is still expanding full research coverage of QTZM. A delayed quote, fundamentals, and analysis are available in the app; the SEC-sourced material below is what we currently have indexed here.
Business summary
Quantumzyme develops engineered enzymes for pharmaceutical and industrial applications using quantum mechanics and molecular modeling.
Source: 10-K (2025-07-31) · AI-generated analysis. Not investment advice. May contain errors.
SEC filings
- 10-Q Quarterly financial report (unaudited) 2026-06-11
- 10-Q/A Amended quarterly report 2026-04-15
- 10-Q/A Amended quarterly report 2026-04-15
- 10-K/A Amended annual report 2026-04-15
- 8-K Entry into material agreement; Other material event; Financial statements and exhibits 2026-04-15
Source: SEC EDGAR.
Annual results
4 years of annual figures for QTZM, as filed with the SEC. Figures are as reported and are not restated or adjusted.
| Fiscal year | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| 2025 | $0 | -$199,269 | -$0.01 |
| 2024 | $0 | -$178,569 | -$0.01 |
| 2018 | $93,550 | -$28,167 | — |
| 2017 | $128,147 | -$32,858 | — |
Source: SEC EDGAR (XBRL company facts). Full statements and ratios in the terminal.
- Open QTZM in the Oxford Ledge terminal — delayed quote, chart, and analysis in the app.
- Browse the covered-stock index
- Learn to analyze stocks yourself
The material above is drawn from public SEC EDGAR filings and is provided for educational purposes, not as investment advice. Live pricing and fundamentals are available in the terminal.